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ABSTRACT
The human protease plasmin plays a crucial role in the capacity of the group A
streptococcus (Streptococus pyogenes; GAS) to initiate invasive disease. The GAS
strain NS88.2 was isolated from a case of bacteremia from the Northern Territory of
Australia, a region with high rates of GAS invasive disease. Mutagenesis of the
NS88.2 plasminogen binding M protein Prp was undertaken to examine the
contribution of plasminogen binding and cell surface plasmin acquisition to virulence.
The isogenic mutant NS88.2prp was engineered whereby four amino acid residues
critical for plasminogen binding were converted to alanine codons in the GAS
genome sequence. The mutated residues were reverse complemented to the wildtype
sequence to construct GAS strain NS88.2prpRC. In comparison to NS88.2 and
NS88.2prpRC, the NS88.2prp mutant exhibited significantly reduced ability to bind
human plasminogen and accumulate cell surface plasmin activity during growth in
human plasma. Utilising a humanised plasminogen mouse model of invasive
infection, we demonstrate that the capacity to bind plasminogen and accumulate
surface plasmin activity plays an essential role in GAS virulence.
Key words: Plasmin, Group A streptococcus, innate immunity
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INTRODUCTION
Streptococcus pyogenes (group A streptococcus, GAS) is the major etiological agent
of a variety of human infections. These include simple pharyngitis (> 600 million
cases per year) and impetigo (> 100 million cases per year), but also life-threatening
invasive infections such as necrotizing fasciitis, bacteremia, and toxic shock
syndrome (> 600,000 cases and 163,000 deaths per year) (1). Over the past two
decades there have been numerous reports of a resurgence in GAS invasive disease of
increasing severity in Western countries (2, 3). Additionally, in developing nations,
the epidemiology of GAS disease is less well-described, and GAS infection remains
endemic in many areas (4). In the Northern Territory of Australia, the incidence of
invasive GAS disease in indigenous communities is extremely high, with rates of
bacteremia reported to be 5 times that seen in the non-indigenous population (4).
Similar to the epidemiology seen in developing countries, a diversity of emm types
are found to be associated with both invasive and endemic infections in the Northern
Territory, and invasive disease is generally secondary to endemic skin infections (1,
4-6).
A mounting body of clinical, epidemiological and experimental evidence suggests an
important role for plasminogen activation in GAS virulence (7, 8). Plasminogen is a
single chain glycoprotein found in plasma and extracellular fluids at concentrations of
approximately 2 μM (9). Cleavage of plasminogen at a single site (Arg560-Val561) by
specific plasminogen activators results in the formation of the two-chain plasmin
molecule, which contains a serine protease active site in the C-terminal region (10).
Human plasminogen can also be activated to plasmin by the GAS protein
streptokinase, as part of a highly species specific plasminogen/streptokinase activator
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complex (11). Plasmin has the ability to degrade fibrin clots, connective tissue and
the extracellular matrix (9, 10). Thus activation of this proteolytic system by GAS
may have significant pathological consequences for the host. A subset of GAS strains
express M proteins that bind plasminogen and plasmin directly and with high affinity.
The first of these M proteins to be identified was PAM, initially identified in M53
serotype GAS (12). Plasminogen-binding motifs in M proteins have been identified in
other GAS serotypes associated with both invasive and non-invasive disease (13).
Plasminogen binding M proteins have been well characterised in vitro (12, 14-20),
however the direct contribution of these proteins to GAS virulence has not been
defined. Whilst the deletion of the PAM gene results in a loss of virulence (7, 14),
this may be due to a loss of other functions such as protection from phagocytosis or
binding of other host molecules attributed to M proteins (21).
The PAM related protein Prp is associated with an S. pyogenes strain isolated from a
severe invasive infection in the Northern Territory. Prp has been shown to interact
with plasminogen via the same mechanism, and with a similar affinity to other
plasminogen binding M proteins. It has also been demonstrated that the plasminogen
binding ability of Prp can be abrogated without resulting in a loss of protein structure
(18). Thus, Prp provides an ideal candidate for examining the contribution of
plasminogen binding M proteins to streptococcal virulence. Here we report the
construction of an isogenic GAS Prp mutant (NS88.2prp) which is attenuated for
plasminogen binding and surface plasmin accumulation. Reverse complementation of
the prp gene to wildtype (NS88.2prpRC) restored both cell surface plasminogen
binding and activation. NS88.2, NS88.2prp and NS88.2prpRC expressed equivalent
levels of hyaluronic acid capsule, streptokinase, α-enolase and GAPDH, and showed
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no difference in the ability to bind fibrinogen, survive in whole blood or interact with
human polymorphonuclear leukocytes. The virulence of the isogenic mutant
NS88.2prp was, however, significantly attenuated in a humanised plasminogen
mouse model of invasive infection, underpinning the central role of plasminogen
binding and surface plasmin accumulation in GAS virulence.
MATERIALS AND METHODS
Bacterial strains and culture methods
GAS strains were routinely cultured in Todd-Hewitt Broth containing 1% yeast
(THBY), or grown on horse blood agar plates (HBA), at 37˚C. GAS strain NS88.2
has been described previously (McKay et al. 2004). Allelic exchange was used to
create NS88.2prp via precise replacement of the wildtype prp gene in GAS strain
NS88.2 with the previously described prpA96A101A107A108 gene, which encodes a protein
that is completely attenuated for plasminogen binding (18). The mutation was
subsequently reverse complemented by the replacement of prpA96A101A107A108 with the
wildtype prp gene to create NS88.2prpRC. Escherichia coli MC1061 was propagated
using Luria Bertani (LB) broth or agar. For selection of the plasmid pHY304 in either
GAS or E. coli, erythromycin was used at a concentration of either 4 µg/ml (GAS) or
500 µg/ml (E .coli) respectively, and bacteria cultured at 30ºC.
Construction of prp mutant GAS strains
GAS mutants were constructed essentially as described previously (22, 23). Both the
wildtype prp gene and the prpA96A101A107A108 gene were previously cloned into the
expression vector pGEX2T (18). In order to facilitate allelic replacement, these genes
were subcloned into the temperature sensitive vector pHY304, which contains the
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gene for erythromycin resistance, using BamHI/EcoRI restriction enzyme digestion
and ligation with T4 DNA ligase. Plasmids were transformed into E.coli MC1061
using standard electroporation procedures, and the recombinant plasmids screened by
DNA sequence analysis using primers PAMN1 and PAMN2 (12) to confirm the
presence of either the mutated or wildtype gene. The resulting plasmids (pHYprp and
pHYprpRC) were transformed into NS88.2, or NS88.2prp respectively, by
electroporation (24). Integration into the chromosome was achieved by 2 h incubation
at the permissive temperature for plasmid replication (30˚C). Following subculture at
37˚C, single crossover insertions were selected using erythromycin resistance
screening. Chromosomal DNA was also screened for the presence of the
erythromycin resistance gene by PCR using primers pHYermF (5’-
GAAGGAGTGATTACATGAAC-3’) and pHYermR (5’-
CATAGAATTATTTCCTCCCG-3’), to avoid the selection of spontaneously resistant
mutants. Serial passage at 30˚C and the removal of antibiotic selection was used to
achieve double crossover. The resulting isogenic mutants NS88.2prp and
NS88.2prpRC containing the prpA96A101A107A108 and prp genes respectively, were
confirmed by DNA sequence analysis using primers M1 and M2 (12). The growth
rates of the wildtype and isogenic mutant strains in THBY were found to be identical
(data not shown).
Vir typing
The Vir regulon was amplified from GAS chromosomal DNA, and the resulting
amplification product subjected to restriction enzyme digestion using HaeIII as
described previously (5).
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Capsule assay
Overnight GAS cultures were used to inoculate fresh THBY, and grown to an OD600
of 0.5-0.6. Capsule was extracted and assayed using the Stains-All method as
described previously (25).
Determination of M protein, streptokinase, GAPDH and -enolase expression
Mutanolysin extracts and GAS culture supernatants from overnight cultures were
prepared as described previously (26). Following SDS-PAGE of the protein samples
according to the method of Laemmli (27), proteins were transferred to nitrocellulose
membrane using a Bio-Rad Trans-Blot apparatus (Bio-Rad, USA). For the
determination of M protein expression, mutanolysin extracts were subjected to
western blot analysis using rabbit polyclonal anti-sera raised against PAM. Specific
rabbit anti-sera were also used to examine expression of the plasminogen receptors
GAPDH and -enolase. TCA precipitated proteins from overnight GAS culture
supernatants were assayed for the presence of streptokinase using rabbit streptokinase
anti-serum. The anti-sera used and the conditions for western blotting have been
described in detail elsewhere (19, 26).
Cell surface plasmin acquisition
Cell surface plasmin activation assays were conducted following incubation of GAS
in human plasma, essentially as described previously (26). Briefly, overnight GAS
cultures were adjusted to OD600 0.5 and incubated with human plasma for 3 h at
37ºC. Following washing twice with PBS /0.01% gelatin/0.01 M EDTA, bacteria
were resuspended in PBS/ 0.01% gelatin, and the plasmin activity of this resuspension
determined using the chromogenic substrate Spectrozyme®PL.
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Binding of human plasminogen and fibrinogen
Bacteria were collected from overnight GAS cultures by centrifugation, and
resuspended to 10% transmission at OD600 in PBS/ 0.01% TWEEN-20. A 250 µl
sample of this cell suspension was used for 125I-plasminogen and 125I-fibrinogen
binding analysis as described previously (13). For analysis of plasminogen and
fibrinogen capture from human plasma, 400 µl of bacterial cell suspension was
pelleted by centrifugation, and resuspended in 100 µl of human plasma. Following a 1
h incubation at 37˚C, bacteria were washed 3 times with 1 ml PBS and bound proteins
eluted by incubation in 50 µl 100 mM Glycine-HCl (pH 2.0) for 15 min at room
temperature. Following centrifugation, the supernatant was collected and 4 µl of 1.5
M Tris-HCl added to 40 µl of protein solution. Following SDS-PAGE and western
transfer as described above, membranes were probed with polyclonal goat anti-human
plasminogen, or polyclonal rabbit anti-human fibrinogen antibodies diluted 1:3000.
Goat anti-rabbit or rabbit anti-goat horse radish peroxidase conjugated secondary
antibodies diluted 1:3000 were used for detection of primary antibody binding.
Membranes were developed by enhanced chemiluminescence.
Growth of GAS in whole blood
Survival of GAS strains in whole blood was determined using the Lancefield method
(28). Fold increase in colony forming units (cfu) was determined by dividing the
number of cfu present after 3 h incubation in heparanized human blood, by the
number of cfu present in the original inoculum, as determined by plating on HBA and
colony counting. Assays were performed in triplicate, using two different blood
donors.
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Polymorphonuclear leukocyte phagocytosis assay
Polymorphonuclear leukocytes (2.5  105 cells) were isolated from fresh human
blood, and incubated with 2.5  106 Alexa-488 labelled GAS in the presence of non-
immune human serum as described previously (29, 30). Cells were analysed using
flow cytometry and the percentage of fluorescent polymorphonuclear leukocytes used
as a measure of phagocytosis.
Humanised plasminogen mouse model of invasive disease
Transgenic humanised plasminogen AlPLG1 mice heterozygous for the human
plasminogen transgene (7) were backcrossed with C57BL/J6 mice. Groups of 10
AlPLG1 mice were infected subcutaneously with 100 µl each of NS88.2, NS88.2prp
or NS88.2prpRC, and survival monitored over a 10 day period. The number of cfu
used for infection was determined by serial dilution of the inoculum, plating on HBA,
and colony counting following overnight incubation at 37˚C.
Statistical Analyses
Differences in the survival of humanised plasminogen transgenic mice infected with
GAS strains were determined by log-rank test. All other data were analysed via one
way analysis of variance with Dunnett’s multiple comparison test. Data sets were
considered significantly different at P < 0.05. All analysis was perfomed using
GraphPad Prism version 4.00.
Ethics Approval
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Ethics permission was obtained from the University of Wollongong ethics committee
prior to the commencement of animal experiments. Volunteers provided informed
consent before blood samples were obtained.
RESULTS
Characterisation of GAS strains NS88.2, NS88.2prp and NS88.2prpRC
The mga regulon of NS88.2, a pattern D GAS strain (13), encodes multiple emm and
emm-like genes (31). As the C-terminal of these gene products are highly conserved
between different emm and emm-like genes, it was important to ensure the integrity of
NS88.2prp (prp gene replaced with prpA96A101A107A108 gene) and NS88.2prpRC
(prpA96A101A107A108 gene replaced with prp gene), and that illegitimate gene
rearrangements had not occurred. The mga regulon from NS88.2, NS88.2prp and
NS88.2prpRC was PCR amplified and a restriction profile generated using HaeIII
(Fig. 1 A). Amplification of the mga regulon from each strain resulted in amplicons
of comparative size (~ 7 kb) and the restriction pattern generated for each strain was
identical, suggesting that integration of modified prp genes into the mga regulon of
NS88.2 did not result in unwanted chromosomal rearrangements. The integrity of the
recombined prp genes in the chromosomes of NS88.2prp and NS88.2prpRC was
confirmed by DNA sequence analysis (results not shown).
To further characterise these strains, the expression of Prp by NS88.2, NS88.2prp and
NS88.2prpRC was examined. Western blot analysis of mutanolysin cell wall extracts
was used to confirm equivalent expression levels of M protein by GAS strains
NS88.2, NS88.2prp and NS88.2prpRC (Fig. 1 B). As expected, mutagenised Prp
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expressed by NS88.2prp displays a modified electrophoretic mobility upon SDS-
PAGE (18). No significant difference in the expression of hyaluronic acid capsule by
NS88.2, NS88.2prp and NS88.2prpRC was evident ( P > 0.05; Fig. 1 C).
Furthermore, each of these strains expressed equivalent amounts of the plasminogen
activator streptokinase (Fig. 1 D), and the other known plasminogen receptors
GAPDH and α-enolase (results not shown). Thus, the techniques used for the
construction of the isogenic NS88.2prp and NS88.2prpRC strains did not result in
changes to the expression of other virulence factors involved in the interaction of
GAS with human plasminogen.
Interaction of NS88.2, NS88.2prp and NS88.2prpRC with innate immune
effectors
A significant factor in GAS virulence is the ability of strains to evade phagocytosis by
host immune cells, and the interaction of GAS with fibrinogen has been shown to
provide protection against phagocytosis by polymorphonuclear leukocytes (32, 33).
Additionally, some GAS strains are able to interact with the plasminogen activation
system indirectly via fibrinogen binding M proteins (34). As such, the interaction of
wildtype and mutant strains with fibrinogen, whole human blood and human
polymorphonuclear leukocytes was investigated.
Incubation of GAS strains in human plasma, and subsequent analysis of the eluted
proteins indicated that NS88.2 wildtype and mutant strains of GAS are able to acquire
fibrinogen from human plasma (Fig. 2 A). Furthermore, in a quantitative analysis of
the binding of 125I-fibrinogen (Fig. 2 B), NS88.2, NS88.2prp and NS88.2prpRC
bound equivalent levels of fibrinogen (P > 0.05). Therefore, it can be assumed that
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fibrinogen mediated interactions with both host immune cells and the plasminogen
activation system will be maintained.
This observation is supported by data from whole blood assays indicating no
significant difference in the ability of NS88.2, NS88.2 prp and NS88.2prpRC to
replicate in whole blood from two separate blood donors (P > 0.05; Table 1).
Importantly, all strains showed a greater than 32-fold increase in population, which is
regarded as the threshold for an intact antiphagocytic capacity (35). Furthermore, in
three independent experiments, no significant difference was seen between the uptake
of GAS strains NS88.2, NS88.2prp or NS88.2prpRC by polymorphonuclear
leukocytes (Fig. 3 P > 0.05). Thus, it appears that the expression of the mutated prp
gene by NS88.2prp does not alter the antiphagocytic properties of NS88.2.
Plasminogen binding analysis
GAS have been found to interact directly with plasminogen via multiple receptors. Of
these receptors, the plasminogen binding M protein has been shown to have the
highest affinity for the circulating form of plasminogen. Additonally, there appears to
be a direct correlation between the presence of a plasminogen binding M protein gene
in the GAS chromosome, and the ability of isolates to bind plasminogen (13).
However, to date, the overall contribution of plasminogen binding M protein to the
acquisition of plasminogen by GAS has not been established. Data presented in
Figure 4 clearly indicates that the abrogation of plasminogen binding by the M
protein Prp significantly decreases the ability of GAS strain NS88.2 to acquire
plasminogen, both from human plasma (Fig. 4 A), and in direct plasminogen binding
assays (Fig. 4 B). The plasminogen binding ability of NS88.2prp was restored by
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reverse complementation with the wildtype prp gene. In addition, the expression of
the mutant Prp protein by NS88.2 completely prevented the acquisition of cell surface
plasmin activity (Fig. 4 C). Thus, it appears that for GAS strains which express
plasminogen binding M proteins, the ability to bind and activate plasminogen at the
cell surface is almost exclusively dependant on the expression of these M proteins.
Virulence in the humanised plasminogen mouse infection model
A mounting body of evidence suggests that the ability to localise plasminogen at the
cell surface is critical for the virulence of certain GAS isolates. The role of M-protein
dependant plasminogen acquisition in virulence was investigated using a humanised
plasminogen transgenic mouse infection model. Following subcutaneous injection of
AlPLG1 mice with either NS88.2, NS88.2prp or NS88.2prpRC, survival was
monitored over a ten day period. Whilst the wildtype strain was highly virulent, with
80% of infected mice dead by day 5, NS88.2prp was significantly attenuated for
virulence in this model of infection (10% mortality ; P < 0.05 ; Fig. 5). Replacement
of the wildtype gene resulted in restoration of virulence equivalent to that of the
wildtype (90% mortality; P > 0.05).
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DISCUSSION
The human plasminogen system has been shown to significantly contribute to GAS
virulence. The introduction of the human plasminogen transgene into C57B/J6 mice
resulted in reduced survival of transgenic mice, in comparison to non-transgenic
littermate control mice, upon GAS subcutaneous infection (7). In the same study,
deletion of the GAS plasminogen activator streptokinase brought about a significant
reduction in virulence of isogenic GAS mutants, in comparison to the wildtype
parental strain (7) . Here, we have demonstrated that the capacity of the plasminogen
binding M protein Prp to bind plasminogen to the GAS cell surface is also a
requirement for full GAS virulence. Whilst displaying intact M protein-mediated
innate immune defense and streptokinase expression equivalent to wildtype, the
isogenic mutant NS88.2prp is reduced in capacity to cause lethal infection in the
humanised plasminogen mouse model of invasive infection. These observations
indicate the capacity to accumulate human plasmin activity at the bacterial surface is
an important additional step in the transition of GAS from asymptomatic or benign
infection to life-threatening invasive disease.
Isolated from a bacteremic infection in the Northern Territory, GAS strain NS88.2
has been shown to bind high levels of plasminogen when compared to other GAS
isolates from this region (13). This strain expresses the PAM related protein Prp,
which functions as a high affinity plasminogen receptor (18). In order to investigate
the contribution of M protein to plasminogen binding and cell surface plasmin
acquisition, mutagenesis of the NS88.2 M protein Prp was undertaken. The isogenic
mutant NS88.2prp was engineered whereby two lysine residues, an arginine and a
histidine residue critical for plasminogen binding by Prp, were converted to alanine
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codons in the GAS genome sequence. Expression of virulence factors α-enolase,
GAPDH and streptokinase, which have been shown to interact with plasminogen (34,
36-38), were unaffected in NS88.2prp. The ability of this isogenic mutant to interact
with fibrinogen, resist phagocytosis by polymorphonuclear leukocytes and grow in
whole blood was unchanged compared to the wildtype parental strain. However,
replacement of the wild type prp gene in NS88.2 with a prp gene encoding a protein
attenuated for plasminogen binding, significantly reduced the ability of this strain to
accumulate both plasminogen and plasmin at the cell surface.
The lack of either plasminogen acquisition or activation in human serum by
NS88.2prp suggests that for GAS expressing plasminogen binding M proteins (PAM-
positive GAS), α-enolase and GAPDH which likely interact with kringle domains 4
and 5 of plasminogen (11, 39), do not significantly contribute to plasminogen binding
and activation. Plasminogen binding M proteins interact with kringle domain 2 of
plasminogen and are specifically co-inherited with the sub-cluster 2b allele of
streptokinase (8). These observations suggest that, for PAM-positive S. pyogenes
strains, the specific interaction between human plasminogen kringle 2 domain, sub-
cluster 2b streptokinase and plasminogen binding M proteins provides selection
pressure for the co-inheritance of these GAS virulence factors (8, 11). A number of
PAM-negative GAS strains, including GAS serotype M1T1, also demonstrate human
plasminogen dependent virulence (7, 26, 40) We therefore hypothesise that PAM-
positive and PAM-negative GAS strains employ differing strategies for surface
plasminogen acquisition and activation. For PAM-negative isolates, the formation of
a trimolecular complex of streptokinase, plasminogen and fibrinogen, bound to the
GAS cell surface via fibrinogen receptors or the plasminogen receptors α-enolase and
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GAPDH may represent an alternative human plasminogen-dependent virulence
pathway employed by this strain set (11, 13, 34, 41).
Previous studies investigating the role of PAM in GAS disease have focused on strain
ALAB49. This isolate was associated with uncomplicated impetigo infection (7, 14).
Studies using the hu-skin-SCID mouse model for streptococcal impetigo found that a
PAM negative isogenic deletion mutant of GAS strain ALAB49 displayed partial
attenuation for virulence when compared to the wild type (14). However, a recently
published animal study of GAS infection showed that in mice expressing the human
plasminogen transgene, infection with the PAM positive GAS strain AP53 resulted in
80% mortality whereas an isogenic mutant of AP53, where the PAM gene was
replaced by an antibiotic resistance cassette, exhibited only minimal virulence (7).
While this observation supports the findings of the present study, the creation of
isogenic PAM deletion mutants may also reduce resistance to phagocytosis (14).
Hence, the contribution of plasminogen binding, resistance to phagocytosis (42), and
other potential polar effects cannot be accounted for. The GAS isogenic mutant
strains NS88.2prp and NS88.2prpRC used in this study were precisely constructed,
were found to have comparable levels of interaction with polymorphonuclear
leukocytes and showed equivalent levels of growth in human blood.
Our results suggest that the plasminogen binding M protein Prp is a critical
requirement for virulence in GAS strain NS88.2. Nonetheless, PAM-negative GAS
are capable of virulent infection. This apparent dichotemy is not unprecedented. In
two seperate studies, isogenic mutagenesis of the fibronectin and fibrinogen binding
protein serum opacity factor (SOF) resulted in a loss of GAS virulence in an animal
model of infection (43, 44). Yet, sof is associated with only 40-50% of GAS isolates
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(45, 46). Similarly, targeted mutagenesis of the fibronectin binding protein FbaA,
which is associated with approximately 70 – 85% of GAS isolates (47-49), resulted
in a significant increase in survival when compared to wildtype GAS in a murine
model of skin infection (47). These examples provide further evidence for the concept
of divergent sets of genotypically distinct GAS isolates exhibiting different virulence
strategies in the face of numerous host defenses.
The requirement for GAS surface plasminogen binding and activation for lethal
murine infection described in this work, suggests an important role for the human
plasminogen activation system in the transition from benign to invasive disease.
Rather than employing a strategy whereby diffuse activation of plasminogen by
streptokinase occurs at or near the site of infection, the formation of active plasmin on
the S. pyogenes surface may allow the bacterium to specifically penetrate innate
immune barriers leading to the breakout of human plasmin decorated GAS cells
systemically. An obvious innate immune defense which would be susceptible to this
form of bacterial offensive strategy would be the fibrinogen layer deposited around
the site of local GAS infection by the host (7).
Recent data indicates that over 660,000 cases of invasive GAS infection occur
worldwide each year. Of these, almost one quarter are fatal (1). In order to establish
invasive infection, S. pyogenes must overcome barriers posed by the host innate
immune response. Our data support the contention that the human plasminogen
activation system plays a central role in this process. The expression of functional Prp
at the GAS cell surface is essential for the virulence of strain NS88.2, suggesting that
other plasminogen binding M proteins of both GAS (13, 16, 50, 51), and different
18
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streptococcal species (52), may play an important role in bacterial dissemination
within the host.
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FIGURE LEGENDS
Figure 1. Characterisation of GAS strains NS88.2, NS88.2prp and NS88.2prpRC. A)
Amplification of the mga regulon of NS88.2 (lane 1), NS88.2prp (lane 2) and
NS88.2prpRC (lane 3), and HaeIII digestion of mga amplification products for
NS88.2 (lane 4), NS88.2prp (lane 5) and NS88.2prpRC (lane 6). Molecular size
markers are given in kilobase pairs (kbp). B) Western blot analysis of mutanolysin
cell wall extracts from NS88.2 (lane 1), NS88.2prp (lane 2) and NS88.2prpRC (lane
3) using rabbit polyclonal anti-PAM antibodies. Bold arrowhead indicates Prp.
Molecular mass markers are given in kilodaltons (kDa). C) NS88.2, NS88.2prp and
NS88.2prpRC produce equivalent levels of hyaluronic acid capsule (mean +/- SD, n =
3; P > 0.05). D) Western blot analysis of TCA precipitated GAS supernatants from
NS88.2 (lane 1), NS88.2prp (lane 2) and NS88.2prpRC (lane 3), using rabbit
polyclonal anti-streptokinase antibodies. Bold arrowhead indicates streptokinase.
Molecular weight markers are given in kilodaltons
Figure 2. Interaction of NS88.2, NS88.2prp and NS88.2prpRC with human
fibrinogen. A) Western blot analysis of eluted cell surface proteins following
incubation in human plasma, using anti-human fibrinogen polyclonal antibodies.
Lane 1, purified fibrinogen; lane 2, NS88.2; lane 3, NS88.2prp; lane 4,
NS88.2prpRC. B) Binding of 125I-fibrinogen by GAS strains NS88.2, NS88.2prp and
NS88.2prpRC (mean +/- SD, n = 6 ; P > 0.05).
Figure 3. Flow cytometric analysis of the uptake of NS88.2, NS88.2prp and
NS88.2prpRC by human polymorphonuclear leukocytes. Panels A-C show
24
24
representative data from a single experiment. Data has been gated to exclude
autofluorescence. Uptake by polymorphonuclear leukocytes, as indicated by the
percentage of flourescent polymorphonuclear leukocytes, of GAS strains A) NS88.2,
B) NS88.2prp and C) NS88.2prpRC. D) Combined data from 3 separate experiments
(mean +/- SD, n = 9; P > 0.05 ).
Figure 4. Interaction of NS88.2, NS88.2prp and NS88.2prpRC with human
plasminogen. A Western blot analysis of eluted cell surface proteins following
incubation in human plasma, using anti-human plasminogen polyclonal antibodies.
Lane 1, purified plasminogen; lane 2, NS88.2; lane 3, NS88.2prp; lane 4
NS88.2prpRC). B) Binding of 125I-plasminogen by GAS strains NS88.2, NS88.2prp
and NS88.2prpRC (mean +/- SD, n = 6 ; P < 0.05). C) Acquisition of cell surface
plasmin activity in human plasma by GAS strains NS88.2, NS88.2prp and
NS88.2prpRC (mean +/- SD, n = 9 ; P < 0.05).
Figure 5. Virulence of NS88.2, NS88.2prp and NS88.2prpRC. Cohorts of 10
humanised plasminogen transgenic mice were subcutaneously infected with 1.13 107
cfu NS88.2 (■), 1.3 107 cfu NS88.2prp (▲) or 2.6  107 cfu NS88.2prpRC (▼).  
Survival was measured over a 10 day period. NS88.2prp was significantly attenuated
for virulence when compared to both NS88.2 and NS88.2prpRC (P < 0.05).
Table 1. Fold increase in bacterial colonies compared to inoculum following growth in 
whole human blood (mean +/- SD, n = 3; P > 0.05). 
 Growth of NS88.2a, b 
 
  Growth of NS88.2prp a, b Growth of NS88.2prpRC a, b
Donor 1 272.3 +/- 32.3   
 
179.3 +/- 46.1 
 
244.3 +/- 59.2 
 
Donor 2 174.3 +/- 67.7 217.7 +/- 95 
 
347.7 +/- 68.3  
a Increase in the number of GAS following 3 h incubation in whole blood, determined by 
dividing the number of cfu in blood following incubation, by the number of cfu in the original 
inoculum.  
b The inoculum in cfu used for experiments usin blood from donor 1 and 2 respectively  
was as follows: NS88.2, 485 and 417; NS88.2prp, 673 and 493; NS88.2prpRC, 603 and 
577.   
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